Repligen has had a mixed run, with the share price at US$162.78 after several years of uneven returns. This puts fresh focus on whether the current market value lines up with the cash the business can generate over time. For anyone considering the stock today, the live question is how that cash flow story stacks up against the recent performance profile. Over the past 5 years, Repligen shares have fallen 40.6%, which puts longer term cash flow prospects under the microscope despite shorter...
Detailed price information for Iqvia Holdings Inc (IQV-N) from The Globe and Mail including charting and trades.
Wasatch Global Investors, an asset management company, released its “Small Cap Growth Strategy” Q3 2026 investor letter. The letter can be downloaded here. The Wasatch Small Cap Growth strategy declined in Q3 2026 but outperformed the Russell 2000 Growth Index, which fell 9.39%. Strong company fundamentals and limited exposure to speculative AI-related stocks supported performance, […]
Motley Fool Press Release.
Detailed price information for Repligen Corp (RGEN-Q) from The Globe and Mail including charting and trades.
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be reporting earnings this Tuesday before market hours. Here’s what to expect.
Detailed price information for Repligen Corp (RGEN-Q) from The Globe and Mail including charting and trades.
Detailed price information for Biolife Solutions (BLFS-Q) from The Globe and Mail including charting and trades.
Tipranks Press Release.
BioLife Solutions (NASDAQ:BLFS) stockholders approved the company’s merger agreement with Repligen Corporation at a special meeting held virtually on Oct. 5, 2026, clearing a key shareholder-vote requirement for the proposed transaction. Roderick de Greef, BioLife’s chief executive officer and chai
This is the newest page. Registered accounts read further back.